About this document
Pediatric Safety Review of Xeglyze by andersonln1184 is a document available to read on EtoBox.
The Pediatric Postmarketing Pharmacovigilance Review evaluates the safety of Xeglyze (abametapir) in pediatric patients under 17 years, focusing on serious adverse events. The review found no new safety signals or serious adverse events reported in the FDA Adverse Event Reporting System (FAERS) as of February 22, 2024. Consequently, the Division of Pharmacovigilance concluded that there are no new pediatric safety concerns for abametapir at this time.
- Author
- andersonln1184
- Language
- EN